Eli Lilly reports that tirzepatide is in clinical trials for autoimmune conditions in patients with obesity or overweight
Among key results, 27.1% of those receiving both therapies vs 5.8% of those receiving ixekizumab alone achieved a 10% weight loss and a 100% PASI score at 36 weeks, according to a press release from Lilly, the manufacturer of both ixekizumab and tirzepatide
1, 2, 3...ready, set, glow
BPC-157 (short for "Body Protection Compound") is one of the most talked-about peptides in the recovery world
Prices have moved fast since semaglutide went off-patent, so we cover the branded and generic options, where people really buy them, and how insurance fits in
To test this hypothesis, we first examined the effects of ferroptosis agents and GPX mutations on lipid peroxidation using BODIPY staining